Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
4
×
Tags
biotech
4
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
4
×
indiana blog main
indiana top stories
life sciences
national
4
×
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
4
×
wisconsin blog main
wisconsin top stories
clinical trials
eli lilly
fremanezumab
teva pharmaceutical
amgen
bristol-myers squibb
calcitonin gene-related peptide
drug prices
eptinezumab
erenumab
fda
galcanezumab
migraine
What
approval
4
×
drug
new
bio
class
companies
fda
migraine
roundup
won
advanced
alnylam’s
amgen
arguments
bff
big
biogen’s
biopharmaceutical
candidates
commercialized
competitors
conference
convo
deals
decades
developed
devoted
disease
drugs
earlier
easl
failures
form
gene
gets
head
kicked
littered
liver
major
Language
Current search:
national
×
biotech
×
" texas top stories "
×
approval
×
photo
×
" detroit top stories "
×
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines